Thomas Copmann
Articles
Biologics: Can There Be Abbreviated Applications, Generics, or Follow-On Products?
Gillian R. Woollett;Christopher Webster;Mark Hayes;Thomas Copmann;Anthony Lubiniecki;Kenneth Seamon;Genesio Murano;John Landis;Robert Garnick;Diane Zezza;James Green
July 1st 2003In this question-and-answer discussion of "generic" biologics, the authors contend small changes in manufacturing of biologics dramatically affect the safety and efficacy of the therapeutic molecule.
Latest Updated Articles
Published: September 11th 2024 | Updated: September 18th 2024
CPHI Pharma Award Finalists Announced for 2024
Published: March 27th 2024 | Updated: June 28th 2024
AbbVie Acquires Landos Biopharma and Gets Full FDA Nod for ADC Product
Published: November 15th 2024 | Updated: November 20th 2024
Solving Challenges with AAV Aggregate Analysis Using a Novel Size Exclusion Particle to Determine CQAs
Published: October 28th 2024 | Updated: November 20th 2024
Cell-based phenotypic screening with Incucyte® Live-Cell Analysis Systems
Published: October 22nd 2024 | Updated: November 20th 2024
Optimizing cGMP Facility Design Space with a Hybrid Approach
Published: October 28th 2024 | Updated: November 20th 2024
Quantifying Chemotherapeutic Cytotoxicity in Glial Cells using AI-Driven Label-Free Cell Analysis
